Xiuchun Chen

机构：Shandong University of Technology, Zhengzhou University, Henan Cancer Hospital · ORCID：0000-0002-7134-7170

发表论文 85 篇 · 总被引 521 次 · h-index 14

代表论文

• De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial (2024 · The Lancet Oncology · 被引 41)
• Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial (2024 · EClinicalMedicine · 被引 11)
• Flood Susceptibility and Risk Assessment in Myanmar Using Multi-Source Remote Sensing and Interpretable Ensemble Machine Learning Model (2026 · ISPRS International Journal of Geo-Information · 被引 6)
• Efficacy and safety of inetetamab plus pertuzumab and nab-paclitaxel as neoadjuvant therapy for HER2+ breast cancer: A single-arm multicenter phase II clinical trial (2025 · Cancer Letters · 被引 4)
• Application of Neoadjuvant Docetaxel plus Cisplatin in Early-Stage Triple-Negative Breast Cancer (HELEN-001): Results from a Phase II Trial (2025 · Clinical Cancer Research · 被引 4)
• Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study (2025 · The Breast · 被引 4)